Discovery of novel glitazones incorporated with phenylalanine and tyrosine: Synthesis, antidiabetic activity and structure-activity relationships

Bioorganic Chemistry

Volumn 45, Issue , 2012, Pages 12-28

  Prashantha Kumar, B R ^a   Baig, Nasir R ^b   Sudhir, Sai ^b   Kar, Koyal ^a   Kiranmai, M ^c   Pankaj, M ^c   Joghee, Nanjan M ^c  

^a JSS COLLEGE OF PHARMACY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c JSS COLLEGE OF PHARMACY   (India)

Author keywords

CoMSIA; Dexamethazone; Glitazones; Glucose uptake activity; Insulin resistance; Thiazolidinediones

Indexed keywords

2 (4 OXO 2 THIOXOTHIAZOLIDIN 3 YL) 3 PHENYLPROPANOIC ACID; 2 (5 BENZYLIDENE 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL) 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 (5 BENZYLIDENE 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL) 3 PHENYLPROPANOIC ACID; 2 [5 (2 CHLOROBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 (2 HYDROXYBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL]PHENYLPROPANOIC ACID; 2 [5 (2,4 DICHLOROBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 (2,4 DICHLOROBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 PHENYLPROPANOIC ACID; 2 [5 (3 NITROBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 (4 CHLOROBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 (4 CHLOROBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 PHENYLPROPANOIC ACID; 2 [5 (4 HYDROXY 3 METHOXYBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 (4 HYDROXYBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 (4 HYDROXYBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 PHENYLPROPANOIC ACID; 2 [5 (4 METHOXYBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 (4 METHOXYBENZYLIDENE) 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 PHENYLPROPANOIC ACID; 2 [5 [(FURAN 2 YL)METHYLIDENE] 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 PHENYLPROPANOIC ACID; 2 [5 [4 (BENZYLOXY) 3 METHOXYBENZYLIDENE] 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 [4 (DIMETHYLAMINO)BENZYLIDENE] 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 PHENYLPROPANOIC ACID; 2 [5 [4 [(2 NITROPHENYLCARBAMOYL)METHOXY] 3 METHOXYBENZYLIDENE] 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 [4 [(4 METHOXYPHENYLCARBAMOYL)METHOXY] 3 METHOXYBENZYLIDENE] 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; 2 [5 [4 [(PYRIDIN 2 YLCARBAMOYL)METHOXY] 3 METHOXYBENZYLIDENE] 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL] 3 (4 HYDROXYPHENYL)PROPANOIC ACID; DEXAMETHASONE; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; PHENYLALANINE; ROSIGLITAZONE; TRIACYLGLYCEROL; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEMIDIAPHRAGM; HISTOPATHOLOGY; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; DRUG EVALUATION, PRECLINICAL; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; LIVER; PHENYLALANINE; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES; TRIGLYCERIDES; TYROSINE;

RATTUS; RATTUS NORVEGICUS;

EID: 84867129562     PISSN: 00452068     EISSN: 10902120     Source Type: Journal    
DOI: 10.1016/j.bioorg.2012.08.002     Document Type: Article

References (52)

1. C.S. Cockram Diabetes mellitus in the Asia-Pacific region Hong Kong Med. J. 6 2000 43 52
2. A.M. Fontbonne, and E.M. Eschwege Insulin and cardiovascular disease Diabet. Care 14 1991 461 469
3. M.I. Harris, K.M. Flegal, C.C. Cowie, M.S. Eberhardt, D.E. Goldstein, R.R. Little, H.M. Wiedmeyer, and D.D. Byrd-Holt Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third national health and nutrition examination survey, 1988-1994 Diabet. Care 21 1998 518 524 (Pubitemid 28172927)
4. G.M. Reaven Banting lecture 1998: role of insulin resistance in human disease Diabetes 37 1988 1988 1595 1607 (Pubitemid 19004941)
5. J.P. Anderson Vora Current concepts of renal: hemodynamics in diabetes J. Diabet. Complicat. 9 1995 304 307
6. C. Day Thiazolidinediones: a new class of antidiabetic drugs Diabet. Med. 16 1999 179 192
7. T.M. Wilson, P.J. Brown, D.D. Sterenbatch, and B.R. Henke The PPARs: from orphan receptors to drug discovery J. Med. Chem. 43 2000 527 550 (Pubitemid 30127149)
8. T. Forst, B. Wilhelm, A. Pfützner, W. Fuchs, U. Lehmann, F. Schaper, M. Weber, J. Muller, T. Konrad, and M. Hanefeld Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk Diabet. Vasc. Dis. Res. 5 2008 298 303
9. S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones, B.G. Kravitz, J.M. Lachin, M.C. O'Neill, B. Zinman, and G. Viberti Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N. Engl. J. Med. 355 2006 2427 2443 (Pubitemid 44903747)
10. A.K. McDonough, R.S. Rosenthal, X. Cao, and K.G. Saag The effect of thiazolidinediones on BMD and osteoporosis Nat. Clin. Pract. Endocrinol. Metab. 4 2008 507 513
11. H.D. Berlie, J.S. Kalus, and L.A. Jaber Thiazolidinediones and the risk of edema: a meta-analysis Diabet. Res. Clin. Pract. 76 2007 279 289 (Pubitemid 46400130)
12. S.E. Nissen, and K.N. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 2007 2457 2471 (Pubitemid 46919772)
13. M.A. Peraza, A.D. Burdick, H.E. Marin, F.J. Gonzalez, and J.M. Peters The toxicology of ligands for peroxisome proliferator-activated receptors Toxicol. Sci. 90 2006 269 295
14. M. Lehrke, and M.A. Lazar The many faces of PPARgamma Cell 123 2005 993 999
15. H. Esterbauer, H. Oberkofler, F. Krempler, and W. Patsch Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) Gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression Genomics 62 1999 98 102
16. B.M. Forman, P. Tontonoz, J. Chen, R.P. Brun, B.M. Spiegelman, and R.M. Evans 15-Deoxy-delta 12,14-prostaglandin j2 is a ligand for the adipocyte determination factor PPARgamma Cell 83 1995 803 812 (Pubitemid 3006324)
17. E. Powell, P. Kuhn, and W. Xu Nuclear receptor cofactors in PPARgamma-mediated adipogenesis and adipocyte energy metabolism PPAR Res. 2007 2007 53843
18. B.M. Spiegelman PPAR-gamma: adipogenic regulator and thiazolidinedione receptor Diabetes 47 1998 507 514 (Pubitemid 28160438)
19. C. Ranjan, and R. Ramanujam Diabetes and insulin resistance associated disorders: disease and the therapy Curr. Sci. 83 2002 1533 1538
20. J.M. Nuss, and A.S. Wagman Recent advances in therapeutic approaches to type 2 diabetes Annu. Rep. Med. Chem. 35 2000 211 220 (Chapter 19)
21. B. Kuhn, H. Hilpert, J. Benz, A. Binggeli, U. Grether, R. Humm, H.P. Maerki, M. Meyer, and P. Mohr Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists Bioorg. Med. Chem. Lett. 16 2006 4016 4020 (Pubitemid 43903212)
22. S. Sundriyal, B. Viswanad, E. Bharathy, P. Ramarao, A.K. Chakraborti, and P.V. Bharatam New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design: synthesis and receptor-binding studies Bioorg. Med. Chem. Lett. 18 2008 3192 3195 (Pubitemid 351721010)
23. T. Sohda, K. Mizuno, E. Imamiya, Y. Sugiyama, T. Fujita, and Y. Kawamatsu Studies on antidiabetic agents. II. synthesis of 5-[4-(1- methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives Chem. Pharm. Bull. 30 1982 3580 3600 (Pubitemid 13210097)
24. B.R. Prashantha Kumar, and M.J. Nanjan Novel glitazones: design, synthesis, glucose uptake and structure-activity relationships Bioorg. Med. Chem. Lett. 20 2010 1953 1956
25. B.R. Prashantha Kumar, B.R. Mukesh Soni, S. Santhosh Kumar, Kuldeep Singh, Mohan Patil, R.B. Nasir Baig, and Laxmi Adhikary Synthesis, glucose uptake activity and structure-activity relationships of some novel glitazones incorporated with glycine, aromatic and alicyclic amine moieties via two carbon acyl linker Eur. J. Med. Chem. 46 2011 835 844
26. T. Tomasic, and L.P. Masic Rhodanine as a privileged scaffold in drug discovery Curr. Med. Chem. 16 2009 1596 1629
27. L. Wang, F. Kong, C.L. Kokoski, D.W. Andrews, and C. Xing Development of dimeric modulators for anti-apoptotic bcl-2 proteins Bioorg. Med. Chem. Lett. 18 2008 236 240
28. D. Hardej, C.R. Ashby Jr., N.S. Khadtare, S.S. Kulkarni, S. Singh, and T.T. Talele The synthesis of phenylalanine-derived c5-substituted rhodanines and their activity against selected methicillin-resistant Staphylococcus aureus strains Eur. J. Med. Chem. 45 2010 5827 5832
29. B.R. Prashantha Kumar, M.D. Karvekar, L. Adhikary, M.J. Nanjan, and B. Suresh Microwave assisted syntheses of thiazolidine-2,4-dione motif and microwave induced efficient synthesis of 5-benzylidene-thiazolidine-2,4-dione and 5-benzylidine-2-thioxo-thiazolidine-4-one compounds J. Heterocycl. Chem. 43 2006 897 903 (Pubitemid 44253561)
30. V.L.M. Guarda, M.A. Pereira, C.A. De Simone, J.C. Albuquerque, S.L. Galdino, and J. Chantegrel Synthesis and structural study of arylidene thiazolidine and benzothiazine compounds Sulfur Lett. 26 2003 17 27
31. L. Youfu, M. Liang, Z. Hao, C. Lijuan, L. Rui, H. Chunmei, Y. Shengyong, Y. Xia, C. Zhizhi, L. Zicheng, G. Yan, H. Jing, H. Gu, Y. Li, and W. Yuquan Discovery of (Z)-5-(4-methoxybenzylidene)-thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin a induced acute liver injury of Balb/C mice J. Med. Chem. 53 2010 273 281
32. E. Walaas, and O. Walaas Effect of insulin on rat diaphragm under anaerobic conditions J. Biol. Chem. 195 1952 367 373
33. R.R. Chattopadhyay, S.K. Sarkar, S. Ganguly, R.N. Banerjee, and T.K. Basa Effect of extract of leaves of Vinca rosea Linn. on glucose utilisation and glycogen deposition by isolated rat hemidiaphargm Ind. J. Physiol. Pharmacol. 36 1992 137 138
34. J.N. Feige, L. Gelman, L. Michalik, B. Desvergne, and Wahli From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions Prog. Lipid Res. 45 2006 120 159 (Pubitemid 43248732)
35. D.P. Rose, and J.M. Connolly Omega-3-fatty acids as cancer chemopreventive agents Pharmacol. Ther. 83 1999 217 244 (Pubitemid 29430123)
36. B.R. Prashantha Kumar, T.K. Praveen, M.J. Nanjan, M.D. Karvekar, and B. Suresh Serum glucose and triglyceride lowering activity of some novel glitazones against dexamethasone induced hyperlipidemia and insulin resistance Ind. J. Pharmacol. 39 2007 299 302 (Pubitemid 351300756)
37. J. Ruzzin, A.S. Wagman, and J. Jensen Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3-inhibitor Diabetologia 48 2005 2119 2130 (Pubitemid 41416925)
38. C. Binnert, S. Ruchat, N. Nicod, and L. Tappy Dexamethasone induced insulin resistance shows no gender difference in healthy humans Diabet. Metab. 30 2004 321 326 (Pubitemid 39280230)
39. R.A. DeFronzo, R.C. Bonadonna, and E. Ferrannini Pathogenesis of NIDDM. A balanced overview Diabet. Care 15 1992 318 368
40. G.M. Reaven The role of insulin resistance in human disease Diabetes 37 1988 1495 1507
41. L.I. William Hepatotoxicity of thiazolidinediones Exp. Opin. Drug Saf. 2 2003 581 586
42. R.M. Todd, L.B. Mark, and M.B. Steve Second-generation thiazolidinediones and hepatotoxicity Ann. Pharmacother. 38 2004 1419 1423
43. J. Kohlroser, J. Mathai, J. Reichheld, B.F. Banner, and H.L. Bonkovsky Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration Am. J. Gastroenterol. 95 2000 272 276 (Pubitemid 30041572)
44. S. Donald, R.D. Verschoyle, P. Greaves, T.W. Gant, T. Colombo, M. Zaffaroni, R. Frapolli, M. Zucchetti, M. D'Incalci, D. Meco, R. Riccardi, L. Lopez-Lazaro, J. Jimeno, and A.J. Gescher Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat Cancer Res. 63 2003 5902 5908 (Pubitemid 37187491)
45. C. Hui, H. Yong-Wen, L. Wen-Qi, and Z. Jing-Hui Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum World J. Gastroenterol. 14 2008 2905 2911
46. M. Clark, R.D. Cramer III, D.M. Jones, D.E. Patterson, and P.E. Simeroth Comparative molecular field analysis (CoMFA): toward its use with 3D-structuralatabases Tetrahedron Comput. Methodol. 3 1990 47 59
47. T. Harada, R.R. Maranpot, A. Enomoto, S. Tamano, and J.M. Ward Changes in the Liver and Gallbladder 1996 ILSI Press Washington, DC pp. 125-201
48. SYBYL Molecular Modelling Software, Version 6.7, Tripos Associates Inc., 1669 Hanley Rd., St. Louis, USA, MO 63144-2913.
49. M. Clark, R.D. Cramer III, and O.N. Van Validation of the general purpose tripos 5.2 force-field J. Comput. Chem. 10 1989 982 1012
50. J. Gasteiger, and M. Marsili Iterative partial equalization of orbital electronegativity a rapid access to atomic charges Tetrahedron 36 1980 3219 3228
51. R.D. Cramer III, D.E. Patterson, and J.D. Bunce Comperative molecular field analysis (COMFA): effect of shape on binding of steroids to carried protein J. Am. Chem. Soc. 110 1988 5959 5967
52. R.D. Cramer III, J.D. Bunce, D.E. Patterson, and L.E. Frank Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies Quant. Struct. Act. Relat. 7 1988 18 25